MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Thoracic Oncology

• Publication date

  2008-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/JTO.0b013e318168d9d4PMID 18379349
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells

  2007cited by this paper
• Cancer Statistics, 2007

  2007cited by this paper
• The Hypoxic Environment in Tumor-Stromal Cells Accelerates Pancreatic Cancer Progression via the Activation of Paracrine Hepatocyte Growth Factor/c-Met Signaling

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Comparative genomic hybridization array analysis and real time PCR reveals genomic alterations in squamous cell carcinomas of the lung.

  2007cited by this paper
• Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors.

  2007cited by this paper
• Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.

  2007cited by this paper
• c‐Met activation in lung adenocarcinoma tissues: An immunohistochemical analysis

  2007cited by this paper
• A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.

  2007cited by this paper
• Hepatocyte growth factor and other fibroblast secretions modulate the phenotype of human bronchial epithelial cells.

  2007cited by this paper
• Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

  2006cited by this paper
• Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.

  2006cited by this paper
• Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

  2006cited by this paper
• Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications.

  2006cited by this paper
• Comparative Genomic Hybridization Array Analysis and Real-Time PCR Reveals Genomic Copy Number Alteration for Lung Adenocarcinomas

  2006cited by this paper
• Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.

  2006cited by this paper
• Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma

  2006cited by this paper
• Cigarette smoking induces overexpression of hepatocyte growth factor in type II pneumocytes and lung cancer cells.

  2006cited by this paper
• Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.

  2006cited by this paper
• A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with Rapamycin

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Genetic Classification of Lung Adenocarcinoma Based on Array-Based Comparative Genomic Hybridization Analysis: Its Association with Clinicopathologic Features

  2005cited by this paper
• Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer.

  2005cited by this paper
• Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.

  2005cited by this paper
• Erlotinib in lung cancer - molecular and clinical predictors of outcome.

  2005cited by this paper
• Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

  2005cited by this paper
• Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.

  2005cited by this paper
• Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFRα, PDGFRβ, and Met in Large-Cell Neuroendocrine Carcinoma of the Lung

  2005cited by this paper
• Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

  2004cited by this paper
• Elevated hepatocyte growth factor level correlates with poor outcome in early-stage and late-stage adenocarcinoma of the lung.

  2004cited by this paper
• Allelic imbalance at loci containing FGFR, FGF, c-Met and HGF candidate genes in non-small cell lung cancer sub-types, implication for progression.

  2003cited by this paper
• Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

  2003cited by this paper
• Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

  2003cited by this paper
• Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death.

  2003cited by this paper
• Met, metastasis, motility and more

  2003cited by this paper
• Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.

  2002cited by this paper
• High expression of Met/hepatocyte growth factor receptor suppresses tumorigenicity in NCI-H1264 lung carcinoma cells.

  2002cited by this paper
• Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization.

  2001cited by this paper
• Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers.

  1998cited by this paper
• Revisions in the International System for Staging Lung Cancer.

  1997cited by this paper
• Expression of c‐met/HGF Receptor in Human Non‐small Cell Lung Carcinomas in vitro and in vivo and Its Prognostic Significance

  1996cited by this paper
• Cancer statistics

  1989cited by this paper
• Molecular cloning of a new transforming gene from a chemically transformed human cell line

  1984cited by this paper

• Binding and dynamics of diferuloylmethane-pyrimidine with C-Met protein

  2025cites this paper
• An optimized NGS Protocol for Detecting De Novo MET Amplification in NSCLC: Prognostic and Therapeutic Implications.

  2025cites this paper
• Identification of Cancer Driver Genes based on Dynamic Incentive Model

  2024cites this paper
• MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature

  2024cites this paper
• MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target

  2023cites this paper
• Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors

  2023cites this paper
• A Systematic Review of Mesenchymal Epithelial Transition Factor (MET) and Its Impact in the Development and Treatment of Non-Small-Cell Lung Cancer

  2023cites this paper
• Amivantamab: A new hope in targeting non-small cell lung cancer.

  2022cites this paper
• Preclinical study of a biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, overcomes MET-driven acquired resistance to EGFR TKIs in EGFR-mutant NSCLC.

  2022cites this paper
• Refining patient selection of MET-activated non-small cell lung cancer through biomarker precision.

  2022cites this paper
• Bioinformatically-expanded next-generation sequencing analysis optimizes identification of therapeutically relevant MET copy number alterations in >50,000 tumors.

  2022cites this paper
• Evidence for frequent concurrent DCUN1D1, FGFR1, BCL9 gene copy number amplification in squamous cell lung cancer.

  2021cites this paper
• Frequency of actionable molecular drivers in lung cancer patients with precocious brain metastases.

  2021cites this paper
• Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

  2021cites this paper
• MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis

  2020cites this paper
• Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer

  2020cites this paper
• Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells

  2020cites this paper
• Molecular and Biological Basis of Lung Cancer-Part I

  2020cites this paper
• MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis

  2020cites this paper
• MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis

  2020cites this paper
• Correlative analysis of gene mutation and clinical features in patients with non-small cell lung cancer

  2019cites this paper
• Management of Locally Advanced Lung Cancer

  2019cites this paper
• De Novo MET Amplification in Chinese Patients With Non–Small‐Cell Lung Cancer and Treatment Efficacy With Crizotinib: A Multicenter Retrospective Study

  2019cites this paper
• Mesenchymal-epithelial transition gene amplification and protein overexpression in stage IV pulmonary adenocarcinoma.

  2019cites this paper
• Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

  2019cites this paper
• Understanding the Mechanisms of Resistance in EGFR-Positive NSCLC: From Tissue to Liquid Biopsy to Guide Treatment Strategy

  2019cites this paper
• new-molecular-drivers-in-nsclc-the-role-of-met

  2019cites this paper
• SHR‐A1403, a novel c‐mesenchymal‐epithelial transition factor (c‐Met) antibody‐drug conjugate, overcomes AZD9291 resistance in non‐small cell lung cancer cells overexpressing c‐Met

  2019cites this paper
• HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers

  2019influential citation
• Oncogene addiction as a foundation of targeted cancer therapy: The paradigm of the MET receptor tyrosine kinase.

  2019cites this paper
• Discovery of novel quinazoline derivatives bearing semicarbazone moiety as potent EGFR kinase inhibitors

  2018cites this paper
• Copy Number Abnormalities and Gene Fusions in Lung Cancer: Present and Developing Technologies

  2018cites this paper
• Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment

  2018cites this paper
• Untying the gordion knot of targeting MET in cancer.

  2018cites this paper
• Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer

  2018cites this paper
• Cigarette smoke enhances oncogene addiction to c‐MET and desensitizes EGFR‐expressing non‐small cell lung cancer to EGFR TKIs

  2018cites this paper
• Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives.

  2018cites this paper
• Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib

  2018cites this paper
• Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression

  2018cites this paper
• Placental and Fetal Effects of Onartuzumab, a Met/HGF Signaling Antagonist, When Administered to Pregnant Cynomolgus Monkeys

  2018cites this paper
• Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer

  2018influential citation
• Genomic Biomarkers in NSCLC

  2018cites this paper
• A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.

  2017cites this paper
• MET Amplification and Response to MET Inhibitors in Stage IV Lung Adenocarcinoma

  2017cites this paper
• The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer

  2017cites this paper
• MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review

  2017cites this paper
• Conséquences de la dérégulation de MET sur le phénotype des cancers bronchiques non à petites cellules EGFR mutés devenus résistant aux inhibiteurs de tyrosine kinase d’EGFR

  2017cites this paper
• Simultaneous quantification of volitinib and gefitinib in rat plasma by HPLC-MS/MS for application to a pharmacokinetic study in rats.

  2017cites this paper
• Heterogeneity of biomarker expression in non-small cell lung cancer /

  2017cites this paper
• MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition

  2017influential citation
• Lung Cancer Biomarkers.

  2017cites this paper
• Analysis of the status of EGFR, ROS1 and MET genes in non-small cell lung adenocarcinoma.

  2017cites this paper
• Comparison of the c‐MET gene amplification between primary tumor and metastatic lymph nodes in non‐small cell lung cancer

  2017cites this paper
• Molecular analysis of circulating cell-free DNA in lung cancer

  2017influential citation
• The End of Nihilism: Systemic Therapy of Advanced Non-Small Cell Lung Cancer.

  2017cites this paper
• Selection and evaluation of new reference genes for RT-qPCR analysis in Epinephelus akaara based on transcriptome data

  2017cites this paper
• Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors

  2017cites this paper
• Lung Cancer: Biomarkers, Tyrosine Kinase Inhibitors and Monoclonal Antibodies

  2017cites this paper
• MEK inhibitors against MET-amplified non-small cell lung cancer

  2016cites this paper
• Biomarker development in MET-targeted therapy

  2016cites this paper
• Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?

  2016cites this paper
• Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis

  2016cites this paper
• Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases.

  2016cites this paper
• Targeting the MET Pathway in Gastric and Oesophageal Cancers: Refining the Optimal Approach.

  2016cites this paper
• Diagnosis and Molecular Classification of Lung Cancer.

  2016cites this paper
• Mitochondrial-Targeting MET Kinase Inhibitor Kills Erlotinib-Resistant Lung Cancer Cells.

  2016cites this paper
• bnormality of the hepatocyte growth factor / MET pathway in pulmonary denocarcinogenesis

  2016cites this paper
• The role of HGF/c-MET signaling pathway in lymphoma

  2016cites this paper
• MicroRNA-31 inhibits lung adenocarcinoma stem-like cells via down-regulation of MET-PI3K-Akt signaling pathway.

  2016cites this paper
• Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.

  2016cites this paper
• Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma

  2016cites this paper
• Scientific Advances in Lung Cancer 2015

  2016cites this paper
• Relationships between Chromosome 7 Gain, MET Gene Copy Number Increase and MET Protein Overexpression in Chinese Papillary Renal Cell Carcinoma Patients

  2015cites this paper
• Ampli fi cation Status in Therapy-Naïve Adeno-and Squamous Cell Carcinomas of the Lung

  2015cites this paper
• Somatic copy number alterations detected by ultra-deep targeted sequencing predict prognosis in oral cavity squamous cell carcinoma

  2015cites this paper
• Targeting the c‐Met Kinase

  2015cites this paper
• Agents in the preclinical development stage for non-small cell lung cancer

  2015cites this paper
• Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK

  2015cites this paper
• Clinicopathological and Survival Analysis of Japanese Patients with Resected Non–Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1, or PIK3CA Gene Amplification

  2015cites this paper
• The many facets of lung adenocarcinoma – a disease comprising distinct molecular subgroups.

  2015cites this paper
• Prognosis, Prediction and Risk Assessment in the Prevention and Treatment of Non-Small Cell Lung Cancer

  2015cites this paper
• Targeting the MET pathway for potential treatment of NSCLC

  2015influential citation
• Significance of EGFR signaling pathway genetic alterations in radically resected non-small cell lung cancers from a Polish cohort. One institutional study.

  2015cites this paper
• NON SMALL CELL LUNG CANCER: CLINICAL IMPLICATIONS AND FUTURE PERSPECTIVES

  2015cites this paper
• Promise and challenges on the horizon of MET-targeted cancer therapeutics.

  2015cites this paper
• Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents.

  2015cites this paper
• MET amplification, protein expression, and mutations in pulmonary adenocarcinoma.

  2015cites this paper
• Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC/ATS/ERS classification

  2015cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1141 Prognosis , Prediction and Risk Assessment in the Prevention and Treatment of Non-Small Cell Lung Cancer

  2015cites this paper
• HGF and NRG1 protein expression are not poor prognostic markers in surgically resected lung adenocarcinoma

  2015cites this paper
• Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?

  2015cites this paper
• Tyrosylprotein sulfotransferase 1 expression is negatively correlated with c‑Met and lymph node metastasis in human lung cancer.

  2015cites this paper
• Activating MET Kinase Rearrangements in Melanoma and Spitz Tumors

  2015cites this paper
• Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations

  2015cites this paper
• Targeting the MET gene for the treatment of non-small-cell lung cancer.

  2014cites this paper
• Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress.

  2014cites this paper
• Increased MET Gene Copy Number but Not mRNA Level Predicts Postoperative Recurrence in Patients with Non–Small Cell Lung Cancer1

  2014influential citation
• Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC

  2014cites this paper
• The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance.

  2014cites this paper
• MET Gene Copy Number Gain is an Independent Poor Prognostic Marker in Korean Stage I Lung Adenocarcinomas

  2014cites this paper